Latest Period
Q1 2026
Security Snapshot
Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) Institutional Ownership
CUSIP: 89422G107
13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026
Institutions Reporting
260
Shares (Excl. Options)
101,356,360
Price
$29.71
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- TVTX on Nasdaq
- Shares outstanding
- 92,930,114
- Price per share
- $40.81
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 101,356,360
- Total reported value
- $3,010,550,209
- % of total 13F portfolios
- 0%
- Share change
- -463,881
- Value change
- -$45,423,056
- Number of holders
- 260
- Price from insider filings
- $40.81
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- TVTX - Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 89422G107.
- 260 institutions reported positions in Q1 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 276 to 260 between Q4 2025 and Q1 2026.
- Reported value moved from $3,903,903,645 to $3,010,550,209.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 260 institutions filings for Q1 2026.
Security key
89422G107
Latest holder period
Q1 2026
13F holders
260
13D/G owners
9
CIK / CUSIP context first
Open Q1 2026 holders
TVTX full holder history
Travere Therapeutics, Inc. SEC filings
Travere Therapeutics, Inc. company facts
Travere Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 89422G107:
Significant Owners of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 12% | -6.9% | $253,331,874 | -$17,690,876 | 10,599,660 | -6.5% | JANUS HENDERSON GROUP PLC | 30 Sep 2025 |
| FMR LLC | 12% | $403,768,185 | 10,567,303 | FMR LLC | 31 Dec 2025 | |||
| BlackRock, Inc. | 7.5% | -21% | $122,617,344 | -$24,357,949 | 6,689,435 | -17% | BlackRock, Inc. | 31 Mar 2025 |
| ARMISTICE CAPITAL, LLC | 5.3% | +26% | $150,350,702 | +$34,799,248 | 4,897,417 | +30% | Armistice Capital, LLC | 31 Mar 2026 |
| STATE STREET CORP | 5.3% | $138,466,547 | 4,756,666 | STATE STREET CORPORATION | 31 Dec 2025 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1% | $139,619,887 | 4,699,424 | Vanguard Capital Management | 31 Mar 2026 | |||
| PERCEPTIVE ADVISORS LLC | 4.8% | -12% | $124,537,820 | -$17,973,533 | 4,278,180 | -13% | Perceptive Advisors LLC | 31 Dec 2025 |
| Rock Springs Capital Management LP | 3.3% | -40% | $53,545,523 | -$37,621,463 | 2,921,196 | -41% | Rock Springs Capital Management LP | 31 Mar 2025 |
| Woodline Partners LP | 2.4% | $38,750,646 | 2,114,056 | Woodline Partners LP | 31 Dec 2024 |
As of 31 Mar 2026, 260 institutional investors reported holding 101,356,360 shares of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX). This represents 109% of the company’s total 92,930,114 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) together control 82% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 12% | 11,419,586 | +8.6% | 0.16% | $339,246,615 |
| FMR LLC | 12% | 10,967,967 | +14% | 0.02% | $325,858,279 |
| BlackRock, Inc. | 8.4% | 7,792,033 | -0.98% | 0% | $231,501,299 |
| STATE STREET CORP | 5.3% | 4,959,988 | +4.3% | 0.01% | $147,361,243 |
| ARMISTICE CAPITAL, LLC | 5.3% | 4,897,417 | +30% | 4.8% | $145,502,259 |
| PERCEPTIVE ADVISORS LLC | 4.5% | 4,142,551 | -3.2% | 2.4% | $123,075,190 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.4% | 4,045,812 | 0% | 0% | $120,201,075 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 3.5% | 3,270,513 | -13% | 0.17% | $97,167,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.5% | 2,369,559 | +11% | 0% | $70,411,435 |
| RENAISSANCE TECHNOLOGIES LLC | 2.1% | 1,966,779 | -12% | 0.09% | $58,433,004 |
| Stephens Investment Management Group LLC | 1.9% | 1,798,466 | +4.5% | 0.73% | $53,432,425 |
| GOLDMAN SACHS GROUP INC | 1.9% | 1,719,721 | -7.9% | 0.01% | $51,092,910 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.8% | 1,709,139 | 0% | 0% | $50,778,520 |
| Kynam Capital Management, LP | 1.7% | 1,569,018 | +203% | 3% | $46,615,525 |
| EMERALD ADVISERS, LLC | 1.7% | 1,557,196 | -2.3% | 1.5% | $46,264,293 |
| TWO SIGMA INVESTMENTS, LP | 1.6% | 1,508,259 | +30% | 0.04% | $44,810,375 |
| Rock Springs Capital Management LP | 1.6% | 1,477,954 | -33% | 2.6% | $43,910,013 |
| BANK OF AMERICA CORP /DE/ | 1.4% | 1,345,111 | -27% | 0% | $39,963,238 |
| Driehaus Capital Management LLC | 1.4% | 1,282,518 | +42% | 0.28% | $38,103,610 |
| MPM BIOIMPACT LLC | 1.2% | 1,133,365 | 2.6% | $33,672,274 | |
| WELLINGTON MANAGEMENT GROUP LLP | 1.1% | 1,022,272 | +28% | 0.01% | $30,371,701 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.1% | 977,000 | -67% | 0.04% | $29,026,670 |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1% | 945,033 | -0.36% | 1.4% | $28,076,930 |
| Nuveen, LLC | 1% | 938,569 | -5.5% | 0.01% | $27,884,885 |
| DEUTSCHE BANK AG\ | 1% | 925,919 | +5% | 0.01% | $27,509,054 |
Institutional Holders of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 101,356,360 | $3,010,550,209 | -$45,423,056 | $29.71 | 260 |
| 2025 Q4 | 102,162,218 | $3,903,903,645 | +$8,111,924 | $38.21 | 276 |
| 2025 Q3 | 100,727,863 | $2,407,390,168 | +$19,761,610 | $23.90 | 235 |
| 2025 Q2 | 100,531,635 | $1,487,836,300 | +$12,972,115 | $14.80 | 207 |
| 2025 Q1 | 98,007,579 | $1,771,747,554 | +$87,075,624 | $17.92 | 214 |
| 2024 Q4 | 95,064,656 | $1,655,970,325 | +$204,069,962 | $17.42 | 194 |
| 2024 Q3 | 82,734,245 | $1,157,476,987 | -$64,293,173 | $13.99 | 175 |
| 2024 Q2 | 87,955,117 | $723,000,948 | +$2,540,410 | $8.22 | 168 |
| 2024 Q1 | 87,706,388 | $676,170,447 | +$11,374,907 | $7.71 | 172 |
| 2023 Q4 | 85,573,515 | $769,316,791 | +$27,493,568 | $8.99 | 162 |
| 2023 Q3 | 82,430,217 | $736,935,857 | -$48,196,261 | $8.94 | 166 |
| 2023 Q2 | 82,714,633 | $1,270,488,775 | -$85,984,898 | $15.36 | 165 |
| 2023 Q1 | 84,151,882 | $1,892,538,812 | +$263,849,900 | $22.49 | 171 |
| 2022 Q4 | 72,978,794 | $1,535,405,782 | +$36,464,951 | $21.03 | 153 |
| 2022 Q3 | 69,779,173 | $1,719,469,986 | -$2,015,044 | $24.64 | 168 |
| 2022 Q2 | 69,489,567 | $1,683,983,339 | +$17,370,839 | $24.23 | 166 |
| 2022 Q1 | 69,479,485 | $1,789,961,946 | +$97,223,694 | $25.77 | 166 |
| 2021 Q4 | 65,477,167 | $2,032,139,426 | +$61,452,684 | $31.04 | 165 |
| 2021 Q3 | 60,858,590 | $1,476,104,164 | +$4,235,576 | $24.25 | 145 |
| 2021 Q2 | 60,583,594 | $883,983,031 | -$73,514,650 | $14.59 | 131 |
| 2021 Q1 | 62,621,768 | $1,563,390,183 | +$254,685,025 | $24.97 | 147 |
| 2020 Q4 | 52,293,956 | $1,423,328,983 | +$1,416,953,984 | $27.26 | 135 |